Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00376519 | Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases | terminated | Phase 1 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00005993 | Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer | terminated | Phase 1 | — | Masonic Cancer Center, University of MinnesotaOTHER |
| 0 |
| Nov 29, 2017 |
| clinicaltrials |
| NCT00369291 | CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant | terminated | Phase 1 | 19 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00618696 | Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia | terminated | Phase 1 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00643240 | Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 1 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00725062 | Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | terminated | Phase 1 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 28 | Stanford UniversityOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02700022 | A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas | terminated | Phase 1 | 1 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00113919 | UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients | terminated | Phase 1 / Phase 2 | 14 | University of ArkansasOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT01581541 | PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin's Lymphoma That Have Not Responded to Standard Treatment | terminated | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Oct 4, 2017 | clinicaltrials |
| NCT00849251 | Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 31 | University of WashingtonOTHER | 1 | Sep 8, 2017 | clinicaltrials |
| NCT00857324 | Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients | terminated | Phase 1 / Phase 2 | 18 | Tiziana MarangonOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT02255162 | Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML | terminated | Phase 1 | 8 | Massachusetts General HospitalOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01085656 | A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS | terminated | Phase 1 | 18 | University of FloridaOTHER | 1 | Aug 8, 2017 | clinicaltrials |
| NCT01383447 | Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2017 | clinicaltrials |
| NCT01034592 | Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia | terminated | Phase 1 | 2 | Jason Robert GotlibOTHER | 1 | Aug 2, 2017 | clinicaltrials |
| NCT01551628 | A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma | terminated | Phase 1 | 1 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Jul 31, 2017 | clinicaltrials |
| NCT00587457 | A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia | terminated | Phase 1 | 11 | MedImmune LLCINDUSTRY | 2 | Jul 6, 2017 | clinicaltrials |
| NCT00496132 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | terminated | Phase 1 / Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Jul 2, 2017 | clinicaltrials |
| NCT01342887 | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01251952 | Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation | terminated | Phase 1 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jun 20, 2017 | clinicaltrials |
| NCT00708721 | Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 11 | University of UtahOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00555048 | Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00934232 | Busulfan in Multiple Myeloma | terminated | Phase 1 | 13 | Guido TricotOTHER | 0 | May 23, 2017 | clinicaltrials |
| NCT01610999 | Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation | terminated | Phase 1 | 7 | Tufts Medical CenterOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT00253721 | Melphalan With BBBD in Treating Patients With Brain Malignancies | terminated | Phase 1 | 21 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 21, 2017 | clinicaltrials |
| NCT01750762 | Lenalidomide After Allo Transplant | terminated | Phase 1 | 1 | Beth Israel Deaconess Medical CenterOTHER | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00560352 | Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma | terminated | Phase 1 | 16 | Bristol-Myers SquibbINDUSTRY | 4 | Mar 13, 2017 | clinicaltrials |
| NCT01954784 | Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma | terminated | Phase 1 | 8 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01504490 | Phase I Study of CS-7017 and Bexarotene | terminated | Phase 1 | 9 | Georgetown UniversityOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT00082225 | LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)(ACDAL) | terminated | Phase 1 | 4 | Baylor College of MedicineOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02234037 | Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60 | terminated | Phase 1 | 3 | Emory UniversityOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT01991938 | Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma | terminated | Phase 1 | 75 | Verastem, Inc.INDUSTRY | 2 | Jan 27, 2017 | clinicaltrials |
| NCT01032148 | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma | terminated | Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01944982 | Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma(HNJ-NKAES-2012) | terminated | Phase 1 / Phase 2 | 7 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 20, 2016 | clinicaltrials |
| NCT01555853 | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | terminated | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Dec 6, 2016 | clinicaltrials |
| NCT01908413 | Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 23 | Curis, Inc.INDUSTRY | 1 | Dec 1, 2016 | clinicaltrials |
| NCT01745354 | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | terminated | Phase 1 | 6 | Robert LowskyOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT00058825 | Stem Cell Transplant for Hematologic Diseases(HIMSUM) | terminated | Phase 1 / Phase 2 | 27 | Baylor College of MedicineOTHER | 1 | Nov 7, 2016 | clinicaltrials |
| NCT00912899 | A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 12 | Cougar Biotechnology, Inc.INDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02047149 | Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia | terminated | Phase 1 | 2 | University of Massachusetts, WorcesterOTHER | 1 | Sep 30, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 7 | Steven P. Treon, MD, PhDOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00004239 | 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment | terminated | Phase 1 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT00313053 | Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia | terminated | Phase 1 | 4 | Clare TwistOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2016 | clinicaltrials |
| NCT00543114 | Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL | terminated | Phase 1 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | May 27, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Dec 2, 2017source: clinicaltrials